Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.
| Revenue (Most Recent Fiscal Year) | $11.16M |
| Net Income (Most Recent Fiscal Year) | $-148.12M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 19.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.68 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1332.33% |
| Net Margin (Trailing 12 Months) | -1327.40% |
| Return on Equity (Trailing 12 Months) | -78.40% |
| Return on Assets (Trailing 12 Months) | -58.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.59 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 96.64M |
| Free Float | 87.46M |
| Market Capitalization | $212.60M |
| Average Volume (Last 20 Days) | 1.18M |
| Beta (Past 60 Months) | 2.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |